In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients

Burns

Volumn 34, Issue 7, 2008, Pages 1033-1036

  Timurkaynak, F ^a   Arslan, H ^a   Kurt Azap, Ö ^a   Serin Senger, S ^a   Başaran, Ö ^a   Ozbalikci Karaman S ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Burn infection; Multidrug resistance; Tigecycline

Indexed keywords

AMIKACIN; AMPICILLIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BURN INFECTION; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS DURANS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS RAFFINOSUS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; TEST STRIP;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; BURNS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCUS AUREUS;

EID: 50949106418     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2008.03.005     Document Type: Article

References (28)

1. Appelgren P., Björnhagen V., Bragderyd K., Jonsson C.E., and Ransjö U. A prospective study of infections in burn patients. Burns 28 (2002) 39-46
2. Oncul O., Yüksel F., Altunay H., Açikel C., Celiköz B., and Cavuşlu S. The evaluation of nosocomial infection during 1-year-period in the burn unit of a training hospital in Istanbul, Turkey. Burns 28 (2002) 738-744
3. Altoparlak U., Erol S., Akcay M.N., Celebi F., and Kadanali A. The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 30 (2004) 660-664
4. Hoban D.J., et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn Microbiol Infect Dis 52 (2005) 215-227
5. Bouchillon S.K., et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 52 (2005) 173-179
6. Oliva M.E., Rekha A., Yellin A., Pasternak J., Campos M., Rose G.M., et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT 00081744]. BMC Infect Dis 5 (2005) 88
7. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J., and Loh E. Tigecycline 200 Study Group Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 26 (2004) 704-714
8. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41 Suppl. 5 (2005) S303-S314
9. Clinical and Laboratory Standards Institute 2005. Methods for disc diffusion antimicrobial susceptibility tests for bacteria that grow aerobically. M100-S14, 7th Ed.
10. European Committee on Antimicrobial Susceptibility Testing Steering Committee (EUCAST). EUCAST technical note on tigecycline. Clin Microbiol Infect 2006;12:1147-9.
11. Insa R., Cercenado E., Goyanes M.J., Morente A., and Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59 (2007) 583-585
12. Pachón-Ibáñez M.E., Jiménez-Mejías M.E., Pichardo C., Llanos A.C., and Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48 (2004) 4479-4481
13. Hawkey P., and Finch R. Tigecycline: in vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 13 (2007) 354-362
14. Wassermann D. Systemic complications of extended burns. Ann Chir Plast Esthet 46 (2001) 196-209
15. Santucci S.G., Gobara S., Santos C.R., Fontana C., and Levin A.S. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 53 (2003) 6-13
16. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
17. Bauer G., Berens C., Projan S.J., and Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53 (2004) 592-599
18. Olson M.W., Ruzin A., Feyfant E., Rush T.S., O'Connell J., and Bradford P.A. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 50 (2006) 2156-2166
19. Sader H.S., Jones R.N., Stilwell M.G., Dowzicky M.J., and Fritsche T.R. Tigecycline activity tested against 26 474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 52 (2005) 181-186
20. Gales A.C., Jones R.N., Andrade S.S., Pereira A.S., and Sader H.S. In vitro activity of tigecycline, a new glycylcycline, tested against 1 326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 9 (2005) 348-356
21. Biedenbach D.J., Beach M.L., and Jones R.N. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 40 (2001) 173-177
22. Patel R., Rouse M.S., Piper K.E., and Steckelberg J.M. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 38 (2000) 177-179
23. Henwood C.J., Gatward T., Warner M., James D., Stockdale M.W., Spence R.P., et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 49 (2002) 479-487
24. Humphreys H., and Towner K.J. Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect 37 (1997) 281-286
25. Van Looveren M., and Goossens H. ARPAC Steering Group Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 10 (2004) 684-704
26. Bouchillon S.K., Hoban D.J., Johnson B.M., Stevens T.M., Dowzicky M.J., Wu D.H., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 51 (2005) 291-295
27. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007) 128-131
28. Navon-Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 772-774